1827-75-4

Basic information

• Product Name: Androstan-17-ol, 3,3-difluoro-, acetate, (5alpha,17beta)-
• Synonyms: Androstan-17-ol, 3,3-difluoro-, acetate, (5alpha,17beta)-;3,3-difluoroandrostane-17-ol acetate;3,3-Difluoro-5alpha-androstan-17beta-yl acetate
• CAS NO: 1827-75-4
• Molecular Formula: C₂₁H₃₂F₂O₂
• Molecular Weight: 0
• Mol File: 1827-75-4.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 393.7°C at 760 mmHg
• Flash Point: 185.3°C
• Appearance: /
• Density: 1.12g/cm³
• Vapor Pressure: 2.08E-06mmHg at 25°C
• Refractive Index: 1.501
• CAS DataBase Reference: Androstan-17-ol, 3,3-difluoro-, acetate, (5alpha,17beta)-(CAS DataBase Reference)
• NIST Chemistry Reference: Androstan-17-ol, 3,3-difluoro-, acetate, (5alpha,17beta)-(1827-75-4)
• EPA Substance Registry System: Androstan-17-ol, 3,3-difluoro-, acetate, (5alpha,17beta)-(1827-75-4)

Safety Data

• Hazardous Substances Data: 1827-75-4(Hazardous Substances Data)

Usage

General Description

Androstan-17-ol, 3,3-difluoro-, acetate, (5alpha,17beta)- is a synthetic chemical compound that belongs to the androstane class of steroids. Androstan-17-ol, 3,3-difluoro-, acetate, (5alpha,17beta)- is a derivative of androstanol, which is a naturally occurring steroid hormone. It is commonly used in research and drug development as a precursor to other bioactive compounds. The presence of the acetate group in this compound makes it more lipophilic and enhances its bioavailability, making it a valuable tool in the study of steroid metabolism and hormone receptor interactions. Additionally, the 3,3-difluoro substitution alters the chemical and biological properties of this compound, making it useful in the development of novel pharmaceuticals and hormone therapies.

InChI:InChI=1/C21H32F2O2/c1-13(24)25-18-7-6-16-15-5-4-14-12-21(22,23)11-10-19(14,2)17(15)8-9-20(16,18)3/h14-18H,4-12H2,1-3H3/t14-,15-,16-,17-,18-,19-,20-/m0/s1

Upstream product

• 1164-91-6 stanolone acetate 
• 19640-01-8 17β-Acetoxy-5α-androstan-3-one hydrazone 
• 521-18-6 Stanolone 

Relevant articles and documents

Synthesis of high affinity fluorine-substituted ligands for the androgen receptor. Potential agents for imaging prostatic cancer by positron emission tomography

We have prepared nine androgens substituted with fluorine at C-16 or C-20 to evaluate their potential, as positron emission tomographic (PET) imaging agents for prostatic cancer when labeled with the positron emitting radionuclide fluorine-18 (t( 1/2 ) = 110 min). These compounds represent members from the following classes of androgens: testosterone (T), 5α- dihydrotestosterone (DHT), 7α-methyl-19-nortestosterone (MNT), mibolerone (Mib), and metribolone (R1881). All of these compounds were prepared by functionalization of suitable androgen precursors, and the synthetic routes were developed to allow the introduction of fluorine by a fluoride ion displacement reaction late in the synthesis, as is required for the preparation of these compounds in fluorine-18 labeled form. We have also prepared four androgens in which the C-3 carbonyl or 17β-hydroxyl groups are replaced by fluorine. Most of the fluorine-substituted androgens show high affinity for the androgen receptor (AR), although fluorine substitution lowers their affinity by a small factor. None of the androgens where fluorine replaces oxygen functions at C-3 or C-17 have substantial affinity for AR. Derivatives of the natural androgens (T and DHT) as well as MNT have little affinity for other steroid hormone receptors (progesterone and mineralocorticoid receptors), whereas the Mib and R1881 derivatives have somewhat greater heterologous binding. With sex steroid binding protein, a human serum binding protein, the pattern of binding affinities is nearly the reverse, with derivatives of Mib, R1881 and MNT having low affinity, and DHT and T, high affinity. From these fluorine-substituted compounds, we can select several whose preparation in fluorine-18 labeled form for further tissue distribution studies is merited.